[HTML][HTML] Overcoming cancer therapeutic bottleneck by drug repurposing
Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …
the development of the alternative strategy of drug repurposing, the development of old …
[HTML][HTML] Bone marrow microenvironment and the identification of new targets for myeloma therapy
K Podar, D Chauhan, KC Anderson - Leukemia, 2009 - nature.com
The development of multiple myeloma (MM) is a complex multi-step process involving both
early and late genetic changes in the tumor cell as well as selective supportive conditions by …
early and late genetic changes in the tumor cell as well as selective supportive conditions by …
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA
in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in …
in cancers including multiple myeloma (MM). Therefore, HDAC inhibitors used alone and in …
[HTML][HTML] EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary
M Sant, C Allemani, M Santaquilani, A Knijn… - European journal of …, 2009 - Elsevier
EUROCARE-4 analysed about three million adult cancer cases from 82 cancer registries in
23 European countries, diagnosed in 1995–1999 and followed to December 2003. For each …
23 European countries, diagnosed in 1995–1999 and followed to December 2003. For each …
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer
E Kupperman, EC Lee, Y Cao, B Bannerman… - Cancer research, 2010 - AACR
The proteasome was validated as an oncology target following the clinical success of
VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring …
VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring …
[HTML][HTML] In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple …
Background Combinations of drug treatments based on bortezomib or lenalidomide plus
steroids have resulted in very high response rates in multiple myeloma. However, most …
steroids have resulted in very high response rates in multiple myeloma. However, most …
[HTML][HTML] Survival trends in European cancer patients diagnosed from 1988 to 1999
A Verdecchia, S Guzzinati, S Francisci… - European journal of …, 2009 - Elsevier
We analysed data from 49 cancer registries in 18 European countries over the period 1988–
1999 to delineate time trends in cancer survival. Survival increased in Europe over the study …
1999 to delineate time trends in cancer survival. Survival increased in Europe over the study …
[HTML][HTML] Proteasome-associated deubiquitinases and cancer
A Mofers, P Pellegrini, S Linder, P D'Arcy - Cancer and Metastasis …, 2017 - Springer
Maintenance of protein homeostasis is a crucial process for the normal functioning of the
cell. The regulated degradation of proteins is primarily facilitated by the ubiquitin …
cell. The regulated degradation of proteins is primarily facilitated by the ubiquitin …
Molecular and cellular mechanisms of CLL: novel therapeutic approaches
The mainstay of therapy of chronic lymphocytic leukemia (CLL) is cytotoxic chemotherapy;
however, CLL is still an incurable disease with resistance to therapy developing in the …
however, CLL is still an incurable disease with resistance to therapy developing in the …
Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine
M Hewish, I Chau… - Recent patents on anti …, 2009 - ingentaconnect.com
The insulin-like growth factor 1 receptor (IGF-1R) and its associated signalling system has
provoked considerable interest over recent years as a novel therapeutic target in cancer. A …
provoked considerable interest over recent years as a novel therapeutic target in cancer. A …